To address this need, we compared the cost-effectiveness of dabrafenib plus trametinib with vemurafenib as the first-line treatments for previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600 mutations from a healthcare system perspective in China. The gene discussed is BRAF; the disease is melanoma.